Ocriplasmin regulatory update

FDA approved a BLA from ThromboGenics for Jetrea ocriplasmin to treat symptomatic vitreomacular adhesion (VMA). The company plans to launch the product in January 2013. The recombinant microplasmin, a truncated form of the natural human protein plasmin, is also under review in the EU. ...